Kerala HC directs Health Ministry, DoP to reply on unaffordability of patented cancer drug Ribociclib
Advertisement
The Kerala High Court has directed the Department of Pharmaceuticals (DoP) and a competent officer of Union Health Ministry to file their reply on the issue of unaffordability of a life-saving patented breast cancer drug, Ribociclib, within one month.
The case concerned a petitioner diagnosed with HER2- Negative Metastatic Breast Cancer who was undergoing 'targeted therapy' treatment. The monthly cost of the medicines for treatment worked out to Rs. 63,480/. However, the petitioner was receiving a monthly pension of Rs. 28000/ only, and, eventually succumbed to her illness.
For more details, check out the link given below:
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.